Table 1 Characteristics of the included trials and participants
Author | Year | Patients | Gender (M/F) | Mean age (year) | Sample | Events/total (intervention) | Events/total (placebo) | Drugs (intervention) | Drugs (control) | Lost visits | Percent of lost visits | Follow-up (month) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Borghi et al. [20] | 1993 | Recurrent calcium stones | I: 18/7 C: 20/5 | I: 46.5 C: 42.8 | 40 | 3/19 | 9/21 | Indapamide | No treatment | 10 | 20% | 36 |
Brocks et al. [10] | 1981 | Recurrent calcium stones | NR | 16–49 | 62 | 5/33 | 5/29 | Bendroflumethiazide | Placebo | 0 | 0 | 48 |
Ettinger et al. [19] | 1988 | Recurrent calcium stones | NR | T: L 49.8, H 49.3 C: 48.9 | 73 | 6/42 | 14/31 | Chlorthalidone | Placebo | NR | NR | 36 |
Fernández-Rodríguez et al. [18] | 2006 | Recurrent calcium stones | NR | NR | 100 | 16/50 | 28/50 | Hydrochlorothiazide | No treatment | 0 | 0 | 36 |
Laerum et al. [17] | 1984 | Recurrent calcium stones | 38/12 | T: 45.8 C: 42.7 | 48 | 5/23 | 12/25 | Hydrochlorothiazide + KCl | Placebo | 2 | 4% | 12–51 |
Mortensen et al. [16] | 1986 | Recurrent kidney stones | All male | 20–49 | 22 | 0/12 | 4/10 | Bendroflumethiazide + KCl | Placebo | 5 | 18.5% | 72 |
Ohkawa et al. [15] | 1992 | Calcium stones with hypercalciuria | I: 45/37 C: 52/41 | I: 48.7 C: 46.9 | 175 | 11/82 | 41/93 | Trichlormethiazide | No treatment | 35 | 16.7% | 6–68 |
Scholz et al. [9] | 1982 | Recurrent calcium calculi | I: 14/11 C: 17/9 | I: 46 C: 41 | 51 | 6/25 | 6/26 | Hydrochlorothiazide | Placebo | 3 | 5.6% | 12 |